Avectas’ Solupore® Transfected Cells Isolated Using Sony’s CGX10 Yield Highly Cytotoxic CAR-T Cells
Date: Tuesday, October 28, 2025, 9 AM PDT | 12 PM EDT | 4 PM GMT | 5 PM CET
This webinar explains how CAR-T cells transfected using Solupore® technology from Avectas and sorted using the CGX10 Cell Isolation System from Sony Biotechnology outperform unsorted cells in single-cell, image-based targeted killing assays.
Isolating and engineering CAR-T cells to enhance their efficacy is an important step in advancing cell therapies. We demonstrate that when used together, the Solupore transfected cells sorted using the CGX10 system yield highly cytotoxic CAR-T cells. This workflow enriches triple-positive CD45RA+, CD62L+, CCR7+ T stem cell memory cells (TSCM) with high purity and viability, which consistently demonstrate superior functionality in single-cell killing assays compared to unsorted cells. The CGX10 system can be effectively integrated both upstream and downstream from the Solupore-based workflow, supporting a streamlined and scalable process for generating potent CAR-T cell therapies.
The CGX10 is a fully closed cell isolation system for GMP-compliant cell production and sorting applications. The innovative system design provides seamless scalability from process development to clinical-scale manufacturing. Avectas’ Solupore technology enhances patient access to autologous T-cell therapies by delivering payloads via a physicochemical mechanism that reversibly permeabilizes the cell membrane, producing healthier engineered cells with a younger memory phenotype.
Key Learning Objectives:
- Learn more about the CGX10 Cell Isolation System
- Explore Solupore transfection technology
- Review data showing the yield of highly cytotoxic CAR-T products
- See how the Solupore process generates healthier, more potent transfected T cells
- Examine how the CGX10 integrates into both upstream and downstream workflows
Who should attend
This webinar will benefit researchers working in the cell therapy space (CAR-T, Treg, NK, stem cell) who are interested in non-viral technology for cell engineering (CAR engineering, or CRISPR-Cas9 editing) and need to develop workflows requiring multiparametric selection. The webinar is ideal for specialists, scientists, and engineers in cell and gene therapy manufacturing at the research, process development, or manufacturing stage who are working on applications such as CAR-Treg or Treg, CAR-T, TIL-based, CAR-NK, immune cell, and stem cell therapy.
Speakers
Claudia Krause, PhD
Researcher
Life Science Technology R&D, Sony Corporation
Japan
Dr. Krause is a researcher in the Life Science Technology R&D Department in the Technology Development Laboratories at Sony in Japan and supports applications for the CXG10 system and ID7000™ Spectral Cell Analyzer. Previously she was assistant professor in the Molecular Radiology Lab at the University of Tokyo and did postdoctoral research in the Tumor Genetics and Immunogenetics Lab at the Max Delbrück Center in Berlin. Claudia holds a PhD in immunology and tumor genetics from Humboldt University and a diploma in biochemistry from Freie Universität in Berlin.
Lisa O’Flynn, PhD
Vice President of Process and Analytical Development
Avectas Ltd
Dublin, Ireland
Since 2019, Dr. O’Flynn has supported the development of the Solupore platform from early R&D to its introduction. Lisa has been in involved in cell therapy R&D for over 15 years, with experience in process and product development, ATMP manufacturing, and early phase trial and regulatory submissions. Prior to Avectas, at Orbsen Therapeutics Ltd, Lisa directed the process development team, bringing multiple products from R&D through to GMP ATMP manufacturing and to four open phase 1/2 clinical trials. Lisa holds a BSc in biotechnology, an MSc in immunology from Imperial College London, and a PhD from NUI Galway.